Article
IL22 Promotes Kras-Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of Stemness Properties.
Cancer immunology research - 1 Jul 2018
Khosravi Nasim, Caetano Mauricio S, Cumpian Amber M, Unver Nese, De la Garza Ramos Cynthia, Noble Oscar, Daliri Soudabeh, Hernandez Belinda J, Gutierrez Berenice A, Evans Scott E, Hanash Samir, Alekseev Andrei M, Yang Yi, Chang Seon Hee, Nurieva Roza, Kadara Humam, Chen Jichao, Ostrin Edwin J, Moghaddam Seyed Javad
Abstract excerpt
Somatic KRAS mutations are the most common oncogenic variants in lung cancer and are associated with poor prognosis. Using a Kras-induced lung cancer mouse model, CC-LR, we previously showed a role for inflammation in lung tumorigenesis through activation of the NF-κB pathway, along with induction of interleukin 6 (IL6) and an IL17-producing CD4+ T-helper cell response. IL22 is an effector molecule secreted by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.